FDA Import Alerts: Why Shipments Get Detained at the Border — and the Compliance Path Back to Market

Most companies learn how FDA import alerts work at exactly the wrong moment. A shipment of dietary ingredients lands at the Port of Los Angeles. Instead of clearing customs in 48 hours, it sits in a bonded warehouse while a Detention Without Physical Examination (DWPE) notice arrives in your inbox. The product is from a foreign manufacturer you’ve worked with for three years. The alert wasn’t on your radar. The storage bill starts immediately.

That scenario plays out hundreds of times a year across every product category FDA regulates — drugs, dietary supplement ingredients, cosmetics, medical devices, food additives. And despite FDA’s Predictive Risk-based Evaluation for Dynamic Import Compliance Targeting (PREDICT) system now flagging shipments algorithmically, too many regulated companies still treat import alert risk as an afterthought in their supplier qualification programs.

That’s an expensive oversight. Here’s what actually happens when an import alert lands — and what the compliance path back to market genuinely requires.

What Actually Triggers an FDA Import Alert

FDA publishes its import alerts publicly at fda.gov/industry/import-alerts — a database covering firms and products subject to DWPE across dozens of product categories. Import alerts are issued when FDA determines that a class of products, or products from a specific manufacturer, appears to violate the Federal Food, Drug, and Cosmetic Act under Section 801(a).

For regulated manufacturers sourcing ingredients or finished goods internationally, the most operationally consequential alerts are:

• Import Alert 66-40: Dietary supplement products from manufacturers with documented GMP deviations under 21 CFR Part 111. This covers firms where FDA inspections found systemic failures — batch record gaps, inadequate identity testing, unqualified raw material suppliers, or poor laboratory controls.
• Import Alert 57-08: Drug and API manufacturers that have refused FDA inspection or accumulated multiple Warning Letters for data integrity violations. This one regularly captures overseas API suppliers to U.S. pharmaceutical manufacturers.
• Import Alert 99-23: Unapproved and misbranded drug products, including dietary supplements found to contain undeclared active pharmaceutical ingredients.

The critical point most quality teams miss: placement on an import alert doesn’t require a finding of imminent consumer harm. FDA can issue a DWPE notice based on a pattern of violations — even ones that predate your current supplier relationship. Under FFDCA Section 801(a), once a product has been refused entry or flagged, the burden of proving admissibility shifts entirely to the importer.

That burden is considerably heavier than it looks on paper.

The Real Cost of Detention Without Physical Examination

Storage and freight costs are the visible part of the damage. A typical shipment detained at a major port — Los Angeles, New York/Newark, Houston — runs $150 to $300 per day in warehouse holding fees, on top of demurrage charges from the carrier. For a full container of dietary ingredients with a 60-day detention period, that’s $15,000 to $25,000 in holding costs before you’ve written a single corrective action.

But the indirect costs are larger, and they compound faster.

When a foreign supplier lands on Import Alert 66-40, domestic manufacturers using that supplier face three simultaneous problems. First, supply chain disruption: every pending shipment from that facility is subject to DWPE — companies running lean inventory face production shutdowns within weeks, not months. Second, qualification reset costs: validating a replacement supplier under 21 CFR Part 111 takes a minimum of three to six months when done properly — full analytical testing, facility audit, specification alignment, and stability data review. You can’t shortcut it without creating a second compliance problem. Third, customer liability exposure: if you’re a contract manufacturer, your downstream customers may invoke quality agreement provisions requiring replacement supplier approval before you can resume supply. Each approval cycle adds time, legal review, and relationship strain.

FDA examines fewer than 2% of regulated imports physically — the PREDICT system handles targeting. But once a firm appears in the import alert database, essentially every shipment from that facility triggers automatic DWPE until the alert is formally resolved. There’s no sampling exemption, no credit for a long history of prior compliant shipments. The flag applies uniformly, retroactively, and without exception.

One more underappreciated dimension: documentation exposure during detention. If a detained shipment’s paperwork — certificates of analysis, manufacturing batch records, supplier audit reports — gets pulled for review and found inconsistent, FDA can escalate from detention to formal refusal of entry and refer the matter for further investigation. What started as a logistics problem becomes an active regulatory action.

Getting Off the List: What FDA Actually Wants to See

Removal from an FDA import alert is a formal petition process. Realistic timelines, in our experience with regulated manufacturers navigating FDA compliance remediation, run 18 to 36 months from the date of initial alert placement — assuming the firm takes immediate, substantive corrective action. That timeline surprises most quality directors. It shouldn’t.

FDA’s removal criteria vary by alert type, but the standard documentation package for a dietary supplement manufacturer on Import Alert 66-40 typically includes:

Comprehensive CAPA documentation. Not a list of corrective actions — evidence that the root cause was identified, the correction was implemented, and its effectiveness was verified across a sustained production period. FDA reviewers are experienced enough to distinguish genuine remediation from paper compliance. A CAPA that closes 12 items generically without tracing each back to a specific inspection observation will get a request for supplemental information, which adds months.

Third-party GMP audit report. A current, full-scope audit from a qualified auditor with demonstrated familiarity with FDA’s inspection approach under 21 CFR Part 111. The audit must directly address every observation from the inspection that triggered the alert — not just confirm that the facility is “in compliance generally.”

Consecutive passing analytical results. Depending on the product and alert classification, FDA may require lot-by-lot release testing from an independent U.S.-based laboratory for a specified number of consecutive shipments before granting unconditional clearance. This isn’t a one-time test — it’s an ongoing demonstration.

Updated quality system documentation. Revised SOPs, current training records, corrected batch record templates — anything that demonstrates the systemic fixes are embedded in daily operations, not just written into a remediation plan that sits in a binder.

The petition routes to FDA’s district office and, depending on the alert classification, may require concurrence from CDER, CFSAN, or another FDA center. There’s no formal expedited pathway. FDA will acknowledge receipt, but processing timelines are not publicly stated and vary substantially.

What routinely delays removal is documentation that answers the wrong questions. Quality teams spend weeks compiling thorough internal CAPA logs and audit reports that don’t specifically close the deficiencies FDA cited. The agency isn’t looking for evidence that your quality system is generally functional — it’s looking for evidence that the exact failure mode that triggered the alert has been permanently corrected. That distinction matters enormously in how you structure the petition package.

How AI-Augmented Compliance Reviews Cut the Removal Timeline

The gap between what a company submits and what FDA needs to see is where AI-assisted regulatory compliance consulting is making a measurable difference — not in weeks, but in months shaved off a process that has no expedited pathway.

At Aurora TIC, we use AI-augmented document review as part of import alert removal support engagements. The core application: we ingest the original FDA inspection report or warning letter, cross-reference it against the client’s proposed CAPA documentation and audit report, then run a structured gap analysis that flags every deficiency the FDA citation raised that the submission package doesn’t explicitly close. For a typical dietary supplement manufacturer’s 40-to-80 page removal petition, that comparative review takes hours rather than the weeks a manual regulatory review consumes.

The second application is pre-petition risk scoring. Before a client submits a removal petition, we model the submission against patterns from prior removal cases — what documentation elements correlate with FDA acceptance, where FDA has historically issued requests for supplemental information, and which deficiency categories (data integrity, identity testing, supplier qualification adequacy) trigger the most scrutiny by product type. That predictive layer doesn’t guarantee FDA approval — nothing does. But it meaningfully reduces the iterative back-and-forth that adds months to removal timelines.

There’s also an upstream use: continuous supplier risk monitoring. AI-assisted review of incoming COAs, automated flagging of specification deviations, and supplier scorecard trending between formal audits extend the surveillance window in a way that annual paper-based reviews simply can’t. Companies that feed their quality data through intelligent systems catch the warning signs of a supplier’s compliance deterioration before FDA does.

The Supplier Qualification Gap That Import Alerts Expose

Import alerts rarely arrive as complete surprises to companies that audit their suppliers rigorously on a continuous basis. What they typically reveal is a gap in ongoing surveillance — the difference between qualifying a supplier once and monitoring them dynamically.

Under 21 CFR Part 111.75, dietary supplement manufacturers must establish and follow written procedures for supplier qualification. The regulation requires qualification. The depth and frequency of ongoing monitoring is left to the manufacturer’s judgment. FDA has increasingly used import alert placements to signal that annual audits — the de facto industry standard — may not be sufficient for high-risk ingredient suppliers.

The practical implication: firms sourcing botanical ingredients, probiotics, or APIs from manufacturers in countries with documented GMP enforcement gaps should be running more frequent remote assessments, requiring quarterly COA trending data, and investigating anomalous test results before the next shipment — not after it’s sitting in a bonded warehouse.

If your supplier qualification program produces a static “approved / not approved” status with annual review cycles, you’re managing import alert risk reactively. The shift to dynamic, data-driven supplier monitoring isn’t a competitive advantage anymore. FDA’s enforcement posture has made it a baseline expectation for companies that want to stay out of the import alert database.

The Most Useful Question to Ask Right Now

If your company sources ingredients or finished products from international manufacturers, the question worth asking today isn’t “are we on an import alert?” It’s: what would our documentation look like if FDA reviewed it this afternoon?

That means checking the import alert database quarterly for every active supplier. It means ensuring supplier qualification files are current, that audit reports are within 12 months, and that incoming material testing data is complete enough to demonstrate identity and quality independently of your supplier’s COA. And it means having a response plan documented before you need one — knowing which regulatory consulting resources you’ll engage, which independent laboratory will handle lot-by-lot release testing, and who internally owns the CAPA process.

Import alerts are recoverable. They’re also largely preventable when your quality system is built around continuous, evidence-based supplier intelligence rather than periodic documentation checkpoints. The companies that exit import alerts fastest aren’t the ones that scramble hardest after a detention notice — they’re the ones that already built the documentation infrastructure before FDA came looking.

Written by Sam Sammane, Founder & CEO, Aurora TIC | Founder, Qalitex Group. Learn more about our team

Reserve early access to our AI audit tools — including AI-augmented import alert readiness reviews. Contact us

Related from our network

• Raw Material Supplier Qualification and COA Verification — How contract testing labs assess incoming ingredient quality and flag COA inconsistencies before they become supply chain crises.
• ISO 17025-Accredited Analytical Testing for Import Compliance — Independent lot-by-lot release testing and identity verification for dietary ingredients subject to DWPE requirements.